As the head of the Computational Neurobiology Laboratory at Salk, Sejnowski’s latest project is poised to delve deeply into the intricate workings of neural circuits involved in working memory. With the NIH award funding $3.5 million over the next five years, his team intends to revolutionize our understanding by leveraging advanced computational models to dissect the dynamical activity of neuronal networks. These models aim to uncover principles that govern how information is temporarily encoded and maintained in the brain, a cornerstone process critical for decision-making and reasoning.

Working memory, a fundamental cognitive system, enables the transient storage and manipulation of information necessary for complex tasks. Despite its significance, the precise neural mechanisms underlying its robustness and capacity limitations remain enigmatic. Sejnowski’s approach utilizes state-of-the-art techniques in computational neuroscience, combining biophysically realistic neural network models with machine learning algorithms to simulate and predict the behavior of large-scale brain circuits. Such technological sophistication promises to elucidate how synaptic plasticity and circuit dynamics coalesce to sustain memory traces in the prefrontal cortex and hippocampus.

This research direction extends beyond theoretical exploration by aiming to address practical concerns related to neuropsychiatric conditions. Memory impairments are pervasive across multiple disorders, including schizophrenia, traumatic brain injury (TBI), and post-traumatic stress disorder (PTSD). By decoding the neural code of working memory with unprecedented granularity, Sejnowski’s team aspires to identify biomarkers and potential therapeutic targets that could alleviate cognitive deficits associated with these afflictions. The translational impact of this project cannot be overstated as it offers hope for interventions that restore normal cognitive function.

Throughout his distinguished career, Sejnowski has consistently pioneered transformative technologies and ideas in neuroscience. His earlier contributions profoundly shaped the study of neuroeconomics, neuroanatomy, neurophysiology, cognitive psychology, and artificial intelligence. A landmark achievement was his 1985 invention of the Boltzmann machine alongside Geoffrey Hinton, PhD, a quantum leap for neural network learning algorithms. The Boltzmann machine represents the first algorithm capable of learning internal representations in multilayer networks, providing a biologically plausible framework that continues to influence the development of AI to this day.

Beyond algorithmic advances, Sejnowski developed NETtalk, an early neural network system that mimicked human speech synthesis by learning to convert written text into phonetic output. This pioneering work laid a critical foundation for the field of deep learning and current technologies like ChatGPT, which simulate language and cognition through complex neural architectures. His dual focus on biological inspiration and computational implementation epitomizes the fusion of neuroscience and artificial intelligence.

Sejnowski’s influence extends deeply into neuroimaging advancements and the exploration of behaviorally relevant neural systems. His recent innovation involves a novel method for precisely measuring synaptic strength and plasticity, vital parameters underpinning learning and memory formation. By quantifying how synapses encode information and undergo activity-dependent changes, this technique sheds light on the synaptic basis of cognitive decline observed in aging and neurodegenerative diseases. Such insights are critical for developing strategies to preserve cognitive function across the lifespan.

Recognition of Sejnowski’s scientific excellence is reflected in the numerous prestigious awards he has garnered over the years. Most notably, he was honored with the 2024 Brain Prize and the 2022 Gruber Prize in Neuroscience, reflecting his outstanding contributions to understanding brain function. These accolades underscore his role as a luminary whose work bridges multiple disciplines and drives progress in the neurosciences.

A testament to his standing in the scientific community, Sejnowski holds positions in several elite academies, including the United States National Academy of Sciences, National Academy of Medicine, National Academy of Engineering, and National Academy of Inventors. He is also a Fellow of the Royal Society in the United Kingdom and a member of the American Philosophical Society, highlighting his global influence as a thought leader and innovator.

The Salk Institute, where Sejnowski conducts his research, is renowned for its relentless pursuit of groundbreaking knowledge in biological sciences. Founded by Jonas Salk, the developer of the first effective polio vaccine, the institute embodies a culture of bold scientific exploration. Within its walls, scientists continually push the boundaries of understanding in neuroscience, cancer biology, aging, immunobiology, and computational biology, among other fields. Sejnowski’s work fits seamlessly into this mission, combining innovation with impact.

Sejnowski’s ongoing commitment to deciphering the biological basis of cognition, learning, and memory signifies a new chapter in brain science. As computational tools grow increasingly sophisticated, melding detailed biophysical models with AI-driven analytics, his laboratory stands at the forefront of unraveling the complexities of neural information processing. This work holds profound implications not only for fundamental neuroscience but also for the development of targeted treatments for cognitive impairments.

With the NIH Director’s Pioneer Award supporting this ambitious endeavor, Terrence Sejnowski’s visionary research will continue to illuminate the neural architecture of working memory. His innovative approach exemplifies the power of interdisciplinary science to tackle some of the most challenging questions in brain function and dysfunction. The coming years promise remarkable advances from his lab that could redefine therapeutic strategies for mental health disorders and enhance our comprehension of the human mind.

Subject of Research: Neural circuit dynamics of working memory and computational modeling of cognitive processes in health and disease.

Article Title: NIH Director’s Pioneer Award Enables Terrence Sejnowski’s Cutting-Edge Computational Exploration of Working Memory Circuitry

News Publication Date: October 13, 2025

Web References:
– https://www.salk.edu/scientist/terrence-sejnowski/
– https://commonfund.nih.gov/pioneer
– https://www.salk.edu/news-release/upgrading-brain-storage-quantifying-how-much-information-our-synapses-can-hold/
– https://www.salk.edu/news-release/salk-professor-terrence-sejnowski-wins-brain-prize/
– https://www.salk.edu/news-release/salk-institutes-terrence-sejnowski-awarded-gruber-prize/
– https://www.salk.edu/news-release/terrence-sejnowski-elected-to-the-royal-society-and-the-american-philosophical-society/

Image Credits: Salk Institute

Keywords: Life sciences, Neuroscience, Cognitive neuroscience, Computational neuroscience, Memory, Cognition, Cognitive psychology, Psychological science, Social sciences

At the forefront of this latest research funding is a diverse array of projects aimed at deciphering complex biological systems and developing novel therapeutic strategies. Among these, one of the most compelling focuses lies in the exploration of neuronal dynamics within the brain. Dr. Ezgi Hacisuleyman, an assistant professor at the institute, has secured a $2.3 million grant from the National Institute of General Medical Sciences. Her work probes the intricate mechanisms neurons use to rapidly alter their structure and function in response to external stimuli. By employing state-of-the-art imaging and molecular labeling techniques, Hacisuleyman’s research delves deeply into the subcellular localization and regulation of RNA and protein synthesis processes that enable neuronal function and plasticity, a pursuit critical to understanding neuropathologies rooted in cellular miscommunication.

Understanding how neurons strategically transport and locally produce RNA molecules challenges existing paradigms in molecular neuroscience. RNAs, beyond their classical role in protein synthesis, participate actively in regulating cellular responses, especially in polarized cells like neurons, where signaling and metabolic needs vary dramatically between dendrites, soma, and axon terminals. Hacisuleyman’s focus on these RNA localization mechanisms could unravel novel pathways implicated in neurological disorders such as Alzheimer’s disease, certain cancers, and inherited genetic conditions, paving the way for targeted RNA-based therapeutics.

Another major thrust of the institute’s research portfolio centers on combating pediatric HIV infection, a global health challenge that remains acute despite advances in antiretroviral therapy. Dr. Mauricio Martins has obtained a grant exceeding $6 million from the National Institutes of Health to explore innovative gene therapy techniques aimed at protecting infants from HIV transmission. In regions where access to conventional antiretroviral drugs is limited, preventing mother-to-child transmission during breastfeeding remains a formidable barrier. Martins’s pioneering work utilizes adeno-associated virus vectors to deliver broadly neutralizing antibody genes that offer durable protection in newborn rhesus macaques against simian-HIV, a promising model for blocking early HIV infection.

Intriguingly, the research uncovered an immune tolerance mechanism that is critical to the success of this gene therapy. Administering these protective antibodies shortly after birth risks triggering an immune response that neutralizes the therapy’s effectiveness. Here, the Martins team’s findings demonstrate that in utero exposure to neutralizing antibodies can induce immune tolerance, effectively preventing detrimental immune activation in infants. This discovery not only enhances the prospect of extending the therapeutic window for HIV prevention but also holds implications for modulating immune responses in autoimmune diseases and improving outcomes in organ transplantation.

Addressing the pressing clinical challenge of cancer relapse, Drs. Michalina Janiszewska and Matthew Disney are leveraging a $300,000 state grant to develop new therapeutic approaches targeting glioblastoma, the most aggressive and lethal type of brain tumor in adults. Despite standard treatment modalities combining chemotherapy and radiation therapy, patient survival gains have remained marginal for over a decade. The team’s research focuses on the tumor’s adaptation to hypoxic conditions — low oxygen environments — which fosters tumor resilience and resistance to therapy.

Their strategy hinges on inhibiting hypoxia-inducible factors, specifically HIF2-alpha, a transcription factor that orchestrates cellular responses to oxygen deficiency and drives tumor progression. By integrating expertise in chemical biology and medicinal chemistry, the researchers are designing small molecules capable of selectively binding messenger RNAs (mRNAs) involved in hypoxia signaling. Targeting the mRNA of HIF2-alpha represents an innovative therapeutic angle that disrupts gene expression at the RNA level, offering precision in modulating pathological pathways. This approach holds promise not only for glioblastoma but potentially for breast cancer metastasis and other hypoxia-associated malignancies.

Further contributing to the antiviral armamentarium, Dr. Susana Valente’s laboratory has secured a five-year, $4.8 million grant from the National Institute of Allergy and Infectious Diseases to advance a novel class of HIV inhibitors. Rather than targeting viral entry or replication enzymes, Valente’s group focuses on Tat, an essential viral protein that functions as a trans-activator of HIV gene transcription. Tat activates the virus from a latent state, initiating a cascade of viral production and toxicity within infected cells. By triggering the cell’s ubiquitin-proteasome system to selectively degrade Tat, Valente’s team is developing molecules that ‘turn off’ the virus’s transcriptional switch, implementing a sophisticated block-and-lock tactic aimed at durable suppression of HIV without ongoing therapy.

This novel Tat-targeting strategy represents a paradigm shift in HIV therapeutics, potentially enabling treatment-free viral remission and reducing the burden of lifelong antiretroviral drug regimens. The research integrates medicinal chemistry innovations with rigorous in vitro and in vivo evaluations, including humanized mouse models and ex vivo human cell systems, to optimize drug candidates and verify their efficacy and safety profiles. Success in this endeavor could revolutionize the management of chronic viral infections and inspire similar transcription-targeted antiviral approaches.

Collectively, these research initiatives exemplify The Wertheim UF Scripps Institute’s commitment to advancing biomedical science through multidisciplinary collaboration and translational research. By harnessing expertise in molecular biology, chemistry, immunology, and clinical science, the institute seeks to translate fundamental discoveries into innovative treatments that address some of the most challenging diseases facing humanity today.

Founded in partnership with Scripps Research and integrated into the University of Florida’s ecosystem in 2022, the institute benefits from a dynamic environment fostering synergy between basic research and drug discovery. This recent infusion of funding underscores confidence in the institute’s vision and capability to impact global health positively.

The awarded grants not only bolster ongoing projects but also cement the institute’s role as a hub for scientific breakthroughs ranging from decoding neuronal communication to developing next-generation antiviral and anticancer therapies. As these research programs unfold, the biomedical community anticipates new insights and clinical applications that may transform treatment paradigms and improve patient outcomes worldwide.

With its distinct blend of foundational science and innovative translational approaches, The Wertheim UF Scripps Institute stands as a model for how interdisciplinary collaboration and sustained investment in biomedical research can accelerate progress toward curing diseases that have long eluded effective therapies.

Subject of Research: Biomedical innovation focusing on neuroscience, HIV treatments, cancer therapeutics, and RNA-targeted drug development.

Article Title: Scientists at The Wertheim UF Scripps Institute Awarded $15.7 Million to Advance Next-Generation Biomedical Research

News Publication Date: Not specified

Web References:

• https://wertheim.scripps.ufl.edu/
• https://directory.ufhealth.org/griffin-patrick-1
• https://directory.ufhealth.org/hacisuleyman-ezgi
• https://directory.ufhealth.org/de-aguiar-martins-mauricio
• https://wertheim.scripps.ufl.edu/2025/07/30/gene-therapy-may-block-hiv-transmission-during-breastfeeding-study-shows/
• https://directory.ufhealth.org/janiszewska-michalina
• https://directory.ufhealth.org/disney-matthew
• https://directory.ufhealth.org/valente-susana

Image Credits: The Wertheim UF Scripps Institute

Keywords: Molecular neuroscience, HIV treatments, biomedical innovation, HIV gene therapy, Tat inhibitor, glioblastoma, hypoxia-inducible factors, RNA therapeutics, antiviral drug development, immune tolerance, pediatric HIV, cancer relapse prevention